California's Toxic-Free Cosmetics Act: Why EU-Compliant Formulas Can Still Fail at the US Border

California’s AB 2762 went into force on January 1, 2025 — banning 24 chemical groups from every cosmetic product sold in the state. Most European brands heard about it. Far fewer had actually audited their formulas against the list before the deadline passed.

The assumption that derails them every time: if it cleared EU Regulation 1223/2009, it must be fine in California. That assumption is wrong, and it’s become one of the most expensive compliance gaps we see from EU manufacturers entering the North American market.

The Law That Reshaped the California Cosmetics Market

California’s Toxic-Free Cosmetics Act (AB 2762, signed September 2020) created one of the strictest ingredient-level regulations on cosmetics anywhere in the world. The 24 banned chemical groups — spanning everything from formaldehyde-releasing preservatives to per- and polyfluoroalkyl substances (PFAS) — apply to every cosmetic product sold in California, regardless of where it was manufactured.

That last point matters. You don’t need a California warehouse or a California distributor to be in scope. If your product is accessible to California consumers — through a US e-commerce channel, a retail partner, or a distributor who ships nationwide — the law applies. And with California’s 40 million consumers representing one of the world’s five largest economies in their own right, most European brands can’t afford to treat it as a niche edge case.

The law arrived at an awkward moment, too. MoCRA — the Modernization of Cosmetics Regulation Act, signed into federal law in December 2022 — was simultaneously rolling out new federal cosmetics requirements: mandatory facility registration, product listing, and enhanced safety substantiation. European brands now face a two-layer requirement. California’s state-level ingredient bans sit on top of MoCRA’s federal framework, and the two don’t always point in the same direction.

Where EU Regulation 1223/2009 and AB 2762 Actually Diverge

This is where the real work begins. EU Regulation 1223/2009 is genuinely comprehensive. Annex II lists over 1,300 substances prohibited from cosmetic products. Annex III specifies a further 300-plus substances that are conditionally permitted — with concentration limits, pH restrictions, and application-type constraints. European formulators work within that architecture every day, and they’re usually right to feel confident in it.

But the EU and California built their prohibited lists from different risk models, different scientific petitioning processes, and very different political timelines. The result: substantial overlap in principle, meaningful divergence in practice.

Triclosan. Under EU Regulation 1223/2009, triclosan appears in Annex III and is permitted in certain rinse-off product categories at concentrations up to 0.3% — hand soaps, shower gels, toothpastes, and face wash among them. California’s AB 2762 bans it outright, with no threshold and no category exceptions. A rinse-off antibacterial hand wash that has been on European pharmacy shelves for a decade could fail a California ingredient screen on this single substance.

PFAS. The European Chemicals Agency has been developing a broad PFAS restriction — one of the most significant regulatory proposals ECHA has ever produced — but it is not yet comprehensively in force for cosmetics as of 2025. California, meanwhile, bans PFAS as a category under AB 2762. Any European brand using fluorinated film-forming polymers in foundations, sunscreens, mascaras, or waterproofing treatments needs to assess this urgently. The EU restriction is coming; California’s is already here.

Formaldehyde and methylene glycol. Both are explicitly banned under AB 2762. The EU framework sets maximum release limits — 0.001% for leave-on products, 0.01% for rinse-off products under Annex III entry 5 — and methylene glycol, which generates free formaldehyde in aqueous solution, has historically occupied a regulatory grey zone in several EU member states. California’s position is binary: present or absent. Formaldehyde-releasing preservatives that comply with the EU release threshold may still violate AB 2762 if they generate detectable formaldehyde in the finished product.

Styrene. Found occasionally as a synthetic fragrance component or as a residual monomer in polymer-based ingredients, styrene appears on California’s AB 2762 list. It’s not always obvious from an INCI declaration alone. Full compositional disclosure from your polymer and fragrance suppliers is the only way to confirm absence.

Isobutylparaben and isopropylparaben. California’s AB 2762 specifically names both as prohibited. If your formulation contains either — whether by original design or as a result of earlier reformulation decisions — you’ll need explicit confirmation of absence before entering the California market.

These aren’t hypothetical edge cases. They represent the kinds of discrepancies that surface during a US retail partner’s compliance review, or during an FDA-initiated market surveillance action under the MoCRA framework, which gives FDA considerably broader authority to request safety data than it held before 2022.

Five Substances European Brands Should Screen Before Their Next US Shipment

Based on the patterns we see when reviewing technical documentation from EU manufacturers approaching the US market for the first time, these five areas carry the highest risk of a California non-conformity:

1. Triclosan — check every rinse-off product, especially antibacterial variants developed or reformulated under the pre-2017 EU framework
2. PFAS-containing film formers — foundations, mascaras, and SPF products using fluoropolymers or PTFE-derived materials
3. Formaldehyde-releasing preservatives — DMDM hydantoin, imidazolidinyl urea, diazolidinyl urea, and quaternium-15 all release formaldehyde; check whether finished-product release levels trigger the AB 2762 prohibition
4. Styrene residuals — particularly in products containing synthetic polymers or complex fragrance compositions; request residual monomer data from suppliers
5. Isobutylparaben and isopropylparaben — verify which specific paraben isomers are present in your preserved formulations, regardless of overall paraben concentration

The audit process isn’t technically complicated, but it requires going back to ingredient suppliers for full compositional disclosure — including processing aids, stabilisers, and known impurities — rather than relying on INCI names alone. An INCI list reflects what was intentionally added to your formula. It doesn’t capture trace-level contaminants, residual monomers, or the breakdown products of reactive ingredients. Those are exactly the components that trigger AB 2762 failures in practice.

Building a California-Ready Technical File

European manufacturers already construct detailed technical dossiers under Regulation 1223/2009 — the Cosmetic Product Safety Report, the Product Information File, the Responsible Person documentation. None of that work is wasted for the US market. But it needs to be supplemented with California-specific layers.

For AB 2762 specifically, you need:

• A California ingredient screen: a line-by-line review of every substance, processing aid, and known impurity against the full AB 2762 prohibited list, not just the INCI declaration
• Supplier declarations: written confirmation from each ingredient supplier that their material does not contain any prohibited substance above a detectable threshold — not a generic safety data sheet, but an explicit declaration against the AB 2762 list
• Reformulation documentation where substitutions have been made, with full before-and-after INCI listing and the rationale recorded
• MoCRA product listing alignment: California compliance feeds directly into your federal obligations — all cosmetic products marketed in the US must now be listed with FDA under MoCRA, and any California non-conformity creates a federal exposure as well

One thing worth understanding about enforcement: California doesn’t operate a standalone ingredient-ban inspection agency. In practice, AB 2762 enforcement surfaces through retailer compliance programs. Major retailers operating in California have their own internal banned-substance lists that reference — and in several cases exceed — the statutory AB 2762 requirements. If a retail partner or US distributor requests a compliance declaration, you should be able to provide it within 48 hours. Brands that can’t often lose the listing.

The Direction of Travel Is Consistent — Even If the Timeline Isn’t

California set the standard, and other US states are following. New York, Maryland, and Washington have introduced or are actively considering ingredient-ban legislation modelled on AB 2762. The federal trajectory under MoCRA points toward stronger FDA authority over ingredient safety. The cumulative picture is a US market that is progressively converging toward stricter ingredient oversight, at both the state and federal level.

For European brands, the practical takeaway is this: the 1,300-plus substance prohibitions in EU Annex II don’t map perfectly onto California’s list. Your CPSR demonstrates that the product is safe for EU consumers; it doesn’t replace a California-specific ingredient screen. And neither replaces MoCRA facility registration.

Your EU compliance framework is excellent preparation for the US market. But it’s not sufficient substitution — and the brands that discover that difference during a retailer compliance review are the ones who didn’t run the California audit early enough.

We work with European brands at every stage of this process: from initial formula screening against the AB 2762 list, to coordinating third-party ingredient testing through our accredited partner-lab network in North America, to building the supplier declaration packages that US retailers and distributors actually require before they’ll place an order. The brands that enter the US market cleanly are the ones who treat California compliance as its own distinct workstream — not a footnote appended to the EU technical file.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry Contact us

Related from our network

• FDA Cosmetic Facility Registration Under MoCRA: What Foreign Manufacturers Must Submit — Qalitex Laboratories covers the mandatory registration and product listing obligations that apply to non-US manufacturers under MoCRA, including timelines and common submission errors.
• Cosmetic Ingredient Safety Testing for North American Market Entry — Androxa outlines how Canadian GMP and Health Canada cosmetic notification requirements interact for European brands expanding across both US and Canadian retail channels simultaneously.